Idiopathic Membranous Nephropathy - Epidemiology Forecast - 2034

Idiopathic Membranous Nephropathy - Epidemiology Forecast - 2034

Key Highlights

Idiopathic Membranous Nephropathy (IMN) is a significant type of glomerular disease characterized by the presence of large amounts of protein in the urine (nephrotic syndrome) and is primarily an autoimmune condition.

IMN is often characterized by the antigens associated with the sub-epithelial immune complex deposits, some of them being phospholipase A2 receptor (PLA2R) and thrombospondin domain-containing 7A (THSD7A).

In 2023, PLA2R, THSD7A, and other antigens were detected in ~23,700, ~890, and ~5,000 IMN patients, respectively, in the US.

The total prevalent population of IMN in 7MM will be ~75,000 cases by 2034.

In 2023, the US accounted for ~40% of all prevalent cases of IMN, while the EU4 and the UK combined for ~35%, and Japan contributed ~25%.

The data highlights Japan as the second-largest contributor after the US to IMN cases.

DelveInsight’s “Idiopathic Membranous Nephropathy (IMN) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Idiopathic Membranous Nephropathy (IMN), historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Idiopathic Membranous Nephropathy (IMN) Disease Understanding and Diagnostic Algorithm

Overview

Idiopathic Membranous Nephropathy (IMN) is a prevalent form of glomerular disease primarily associated with nephrotic syndrome. It is characterized by the immune system's attack on the glomeruli, leading to significant proteinuria, edema, and potential progression to renal failure. The condition is termed ""idiopathic"" when no identifiable secondary cause is found, although it can also arise from various underlying conditions, including autoimmune diseases and infections. IMN typically affects adults, particularly middle-aged men, and presents with symptoms such as frothy urine, swelling in the legs and abdomen, and weight gain due to fluid retention.

A detailed overview will be provided in the final report…

Diagnosis

The diagnosis of IMN involves a combination of clinical evaluation and laboratory tests. Initial assessments typically include urine analysis to detect proteinuria, which is often in the nephrotic range (>3.5 g/day). Blood tests are conducted to evaluate kidney function and check for hypoalbuminemia and dyslipidemia, common in nephrotic syndrome. A definitive diagnosis is usually confirmed through a kidney biopsy, which reveals characteristic changes in the glomeruli, such as immune complex deposition along the capillary walls. Additionally, serological tests for specific antibodies, such as those against the phospholipase A2 receptor (PLA2R), can help differentiate primary IMN from secondary forms, guiding further management strategies.

Further details related to diagnosis are provided in the report…

Idiopathic Membranous Nephropathy (IMN) Epidemiology

The Idiopathic Membranous Nephropathy (IMN) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases, antigen-specific cases, and total treated cases of Idiopathic Membranous Nephropathy (IMN) .in the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

In 2023, the US accounted for ~40% of all prevalent cases of IMN in 7MM.

Japan's data suggests a relatively stable trend in the prevalence of IMN over the forecasted period of 2024-2034.

Germany had the highest prevalence of IMN among the EU4 and the UK, accounting for ~30% of cases, followed by the UK with ~20%, in 2023.

In 2023, the PLA2R-specific cases in EU4 and the UK contributed ~75% of the 7MM.

Scope of the Report

The report covers a segment of key events, an executive summary, and a descriptive overview of Idiopathic Membranous Nephropathy (IMN), explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.

Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.

A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.

Idiopathic Membranous Nephropathy (IMN) Report Insights

Patient Population

Total prevalent cases, antigen-specific cases, and total treated cases of Idiopathic Membranous Nephropathy (IMN).

Country-wise Epidemiology Distribution

Idiopathic Membranous Nephropathy (IMN) Report Key Strengths

Eleven-year Forecast

The 7MM Coverage

Idiopathic Membranous Nephropathy (IMN) Epidemiology Segmentation

Idiopathic Membranous Nephropathy (IMN) Report Assessment

Epidemiology Segmentation

Current Diagnostic Practices

FAQs

Epidemiology Insights

What are the disease risks, burdens, and unmet needs of Idiopathic Membranous Nephropathy (IMN)? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Idiopathic Membranous Nephropathy (IMN)?

What is the historical and forecasted Idiopathic Membranous Nephropathy (IMN) patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?

What is the diagnostic pattern of Idiopathic Membranous Nephropathy (IMN)?

Which clinical factors will affect Idiopathic Membranous Nephropathy (IMN)?

Which factors will affect the increase in the diagnosis of Idiopathic Membranous Nephropathy (IMN)?

Reasons to buy

Insights on disease burden, details regarding diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

To understand the change in Idiopathic Membranous Nephropathy (IMN) cases in varying geographies over the coming years.

A detailed overview of total diagnosed prevalent cases of Idiopathic Membranous Nephropathy (IMN), onset age-specific cases, symptom-specific cases, type-specific cases, and total diagnosed cases of Idiopathic Membranous Nephropathy (IMN) is included.

To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the treatment-eligible patient pool.

Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.